Hill-Rom subsidiary Comfort Holdings has acquired all outstanding shares of Tridien Medical, which makes patient positioning devices and support surfaces.

Lundbeck has chalked up another Phase III failure for the Alzheimer's field. Neither dose hit the primary endpoint or showed separation from placebo.

AC Immune is offloading 6 million IPO shares, 32% more than originally planned, at the bottom end of its targeted $11 to $13 price range.

Daniel Soland has quit as CEO of uniQure "due to personal family reasons" 9 months after taking the job.

Diagnostics player T2 Biosystems nabbed $40 million in a private placement from Canon U.S.A, which it will use to boost its business and drive the development…

Spirox is touting results from a study of its Latera absorbable nasal implant, a device designed to fight nasal valve collapse and obstruction.

BioNTech lands a $310 million Genentech deal, a DNA repair startup raises $33 million and Alnylam commits to Britain. And more.

Teva has posted positive Phase III data for its involuntary twitch candidate deutetrabenazine as its gears up for a 2016 FDA filing--putting it a few months…

Gilead said in a brief update that it will be canning its combined Phase II/III test of its experimental GI med GS-5745 after finding that there was “…